Gallium Ga-68 gozetotide
DCTPepD ID DCTPepD0020
Active Ingredients Gallium Ga-68 gozetotide
Description Gallium (Ga) 68 prostate-specific membrane antigen (PSMA)-11, or Ga-68 gozetotide, is a radiopharmaceutical agent used to identify and assess prostate-specific membrane antigen (PSMA)-positive lesions in adult men with prostate cancer during positron emission tomography (PET). In nearly all prostate cancers, malignant cells express a transmembrane protein called prostate-specific membrane antigen (PSMA). Ga-68 PSMA-11 is an imaging agent that binds PSMA during positron emission tomography: it emits positrons to indicate the presence of PSMA-positive prostate cancer lesions in patients with suspected prostate cancer or in patients who may have recurrent prostate cancer.
Synonyms Ga-68 gozetotide; (68)Ga labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC; (68)Ga-labeled Glu-urea-Lys(Ahx)-HBED-CC; (68)Ga-PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC; (68)Gallium-PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC; (68Ga)Glu-urea-Lys(Ahx)-HBED-CC; 68Ga-DKFZ-PSMA-11; 68Ga-HBED-CC-PSMA; 68Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC; 68Ga-PSMA; 68Ga-PSMA-11; 68Ga-PSMA-HBED-CC; [68Ga] Prostate-specific Membrane Antigen 11; [68Ga]GaPSMA-11; Ga PSMA; Ga-68 labeled DKFZ-PSMA-11; Ga-68 labeled PSMA-11; GA-68 PSMA-11; Gallium Ga 68 Gozetotide; Gallium Ga 68 PSMA-11; Gallium Ga 68-labeled PSMA-11; Gallium-68 PSMA; Gallium-68 PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC; GaPSMA; PSMA-HBED-CC GA-68; Gallium Ga-68 gozetotide
Disease Prostatic Neoplasms
Classification
Peptide and derivative Cancer Targeted Radioconjugates
Structure Information
Molecular Formula C44H59GaN6O17
Molecular Weight 1011.9
Active Sequence Not available
Sequence Length Not available
Modification Not available
IUPAC Name (68Ga)gallium(3+) 3-(3-{[(2-{[(5-{2-[(5-{[(5S)-5-carboxy-5-({[(1S)-1,3-dicarboxypropyl]carbamoyl}amino)pentyl]carbamoyl}pentyl)carbamoyl]ethyl}-2-hydroxyphenyl)methyl](carboxylatomethyl)amino}ethyl)(carboxylatomethyl)amino]methyl}-4-hydroxyphenyl)propanoate
InChI InChI=1S/C44H62N6O17.Ga/c51-34-13-8-28(22-30(34)24-49(26-40(59)60)20-21-50(27-41(61)62)25-31-23-29(9-14-35(31)52)11-16-38(55)56)10-15-37(54)46-18-4-1-2-7-36(53)45-19-5-3-6-32(42(63)64)47-44(67)48-33(43(65)66)12-17-39(57)58;/h8-9,13-14,22-23,32-33,51-52H,1-7,10-12,15-21,24-27H2,(H,45,53)(H,46,54)(H,55,56)(H,57,58)(H,59,60)(H,61,62)(H,63,64)(H,65,66)(H2,47,48,67);/q;+3/p-3/t32-,33-;/m0./s1/i;1-2
InChI_Key AEBYHKKMCWUMKX-LNTZDJBBSA-K
SMILES O=C(CCC1=CC=C(C(CN(CC([O-])=O)CCN(CC2=CC(CCC(NCCCCCC(NCCCC[C@@H](C(O)=O)NC(N[C@H](C(O)=O)CCC(O)=O)=O)=O)=O)=CC=C2O)CC([O-])=O)=C1)O)[O-].[68Ga+3]
External Codes
PubChem CID 154572876
DrugBank Accession Number DB16019
NCI Thesaurus Code C118961
UNII ZJ0EKR6M10 GSRS
CAS 1906894-20-9
Drug approval
Drug indication
Gallium Ga-68 gozetotide, or Gallium Ga-68 PSMA-11, is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA)-positive lesions in patients with suspected prostate cancer metastasis who are also candidates for initial surgical or radiation therapy. It is also indicated for patients with suspected prostate cancer recurrence based on elevated serum prostate-specific antigen (PSA) levels.
The drug is not approved.
| ClinicalTrials.gov Identifier | Title | Condition or disease | Phase | Purpose |
|---|---|---|---|---|
| NCT03903419 | Feasibility Study for the Realization of 68Ga-PSMA PET-CT and 18F-FDOPA PET-CT for Identification of Early Recurrence in Patients Treated With Radiotherapy for Glioblastoma | Glioblastomas | Not Applicable | Diagnostic |
| NCT03675451 | PSMA Imaging of Localized Prostate Cancer | Prostate Cancer | Phase 2 | Diagnostic |
| NCT05214820 | Clinical Assessment of the Therapeutic Potential of 177Lu-PSMA Endoradiotherapy for the Treatment of Upper Metastatic Gastric Cancers Using 68Ga-PSMA PET-based Dosimetry | Upper Digestive Tract Cancer | Phase 2 | Diagnostic |
| NCT02918357 | Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence | Prostate Cancer | Phase 2/3 | Diagnostic |
| NCT02919111 | Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients | Prostate Cancer | Phase 2/3 | Diagnostic |
More clinical information is obtained from ClinicalTrials.gov.
